FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

• मुख्य लेखकों: Shike Yan (लेखक), Bing Zhang (लेखक), Jingwen Feng (लेखक), Haigang Wu (लेखक), Namin Duan (लेखक), Yamin Zhu (लेखक), Yueliang Zhao (लेखक), Shuang Shen (लेखक), Kai Zhang (लेखक), Wenhui Wu (लेखक), Ning Liu (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been used as a first-line treatment for patients harboring with EGFR mutations in advanced NSCLC. Nevertheless, the drug resistance aft...